969 related articles for article (PubMed ID: 17980240)
21. Risk factors and clinical outcomes of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli septicemia at Srinagarind University Hospital, Thailand.
Anunnatsiri S; Towiwat P; Chaimanee P
Southeast Asian J Trop Med Public Health; 2012 Sep; 43(5):1169-77. PubMed ID: 23431823
[TBL] [Abstract][Full Text] [Related]
22. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli.
Rooney PJ; O'Leary MC; Loughrey AC; McCalmont M; Smyth B; Donaghy P; Badri M; Woodford N; Karisik E; Livermore DM
J Antimicrob Chemother; 2009 Sep; 64(3):635-41. PubMed ID: 19549667
[TBL] [Abstract][Full Text] [Related]
23. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology.
Rodríguez-Baño J; López-Cerero L; Navarro MD; Díaz de Alba P; Pascual A
J Antimicrob Chemother; 2008 Nov; 62(5):1142-9. PubMed ID: 18641033
[TBL] [Abstract][Full Text] [Related]
24. Molecular epidemiology of multiresistant Escherichia coli isolates from community-onset urinary tract infections in Cornwall, England.
Woodford N; Kaufmann ME; Karisik E; Hartley JW
J Antimicrob Chemother; 2007 Jan; 59(1):106-9. PubMed ID: 17090553
[TBL] [Abstract][Full Text] [Related]
25. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
26. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel.
Laupland KB; Church DL; Vidakovich J; Mucenski M; Pitout JD
J Infect; 2008 Dec; 57(6):441-8. PubMed ID: 18990451
[TBL] [Abstract][Full Text] [Related]
27. Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital.
Graffunder EM; Preston KE; Evans AM; Venezia RA
J Antimicrob Chemother; 2005 Jul; 56(1):139-45. PubMed ID: 15917283
[TBL] [Abstract][Full Text] [Related]
28. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
[TBL] [Abstract][Full Text] [Related]
30. Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women.
Ho PL; Poon WW; Loke SL; Leung MS; Chow KH; Wong RC; Yip KS; Lai EL; Tsang KW;
J Antimicrob Chemother; 2007 Jul; 60(1):140-4. PubMed ID: 17496058
[TBL] [Abstract][Full Text] [Related]
31. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15.
Yumuk Z; Afacan G; Nicolas-Chanoine MH; Sotto A; Lavigne JP
J Antimicrob Chemother; 2008 Aug; 62(2):284-8. PubMed ID: 18453527
[TBL] [Abstract][Full Text] [Related]
32. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)].
Hernández JR; Pascual A; Cantón R; Martínez-Martínez L;
Enferm Infecc Microbiol Clin; 2003 Feb; 21(2):77-82. PubMed ID: 12586030
[TBL] [Abstract][Full Text] [Related]
33. Detection of drug-resistant Escherichia coli in patients with complicated cystitis: analysis of risk factors.
Shigehara K; Uchibayashi T; Maeda E; Namiki M
Int J Urol; 2009 Oct; 16(10):808-12. PubMed ID: 19659550
[TBL] [Abstract][Full Text] [Related]
34. [Risk factors and prognosis in 31 patients with extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bloodstream infection].
Chen YH; Yao WZ; Wu R; Zhou QT; Liu ZY; Zhang XW
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):815-9. PubMed ID: 19080534
[TBL] [Abstract][Full Text] [Related]
35. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.
Fan NC; Chen HH; Chen CL; Ou LS; Lin TY; Tsai MH; Chiu CH
J Microbiol Immunol Infect; 2014 Oct; 47(5):399-405. PubMed ID: 23834784
[TBL] [Abstract][Full Text] [Related]
36. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
[TBL] [Abstract][Full Text] [Related]
37. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Kang CI; Song JH; Chung DR; Peck KR; Ko KS; Yeom JS; Ki HK; Son JS; Lee SS; Kim YS; Jung SI; Kim SW; Chang HH; Ryu SY; Kwon KT; Lee H; Moon C; Shin SY;
Int J Antimicrob Agents; 2010 Sep; 36(3):284-7. PubMed ID: 20580534
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
Azap OK; Arslan H; Serefhanoğlu K; Colakoğlu S; Erdoğan H; Timurkaynak F; Senger SS
Clin Microbiol Infect; 2010 Feb; 16(2):147-51. PubMed ID: 19689464
[TBL] [Abstract][Full Text] [Related]
40. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
